Maria Hagnäs1, Henry Sundqvist2, Jari Jokelainen3, Andrea Tumminia4, Federica Vinciguerra4, Carla Loreto5, Lucia Frittitta4, Giuseppina T Russo6, Ilona Mikkola2. 1. Center for Life Course Health Research, University of Oulu, Oulu, Finland; Rovaniemi Health Center, Rovaniemi, Finland; Endocrine Section, Department of Clinical and Experimental Medicine, University of Catania, and Diabetes and Obesity Unit, Garibaldi Hospital, Catania, Italy. Electronic address: maria.hagnas@rovaniemi.fi. 2. Rovaniemi Health Center, Rovaniemi, Finland. 3. Center for Life Course Health Research, University of Oulu, Oulu, Finland. 4. Endocrine Section, Department of Clinical and Experimental Medicine, University of Catania, and Diabetes and Obesity Unit, Garibaldi Hospital, Catania, Italy. 5. Anatomy & Histology Section, Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. 6. Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Abstract
AIMS: To estimate the prevalence of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) in Finnish primary healthcare, and to evaluate the screening for CKD and the proportions of patients receiving antihyperglycemic and cardiovascular preventive medication. MATERIAL AND METHODS: T2D patients treated at the Rovaniemi Health Center, Finland during the years 2015-2019. Data included patient characteristics, blood pressure, HbA1c, lipid levels, kidney function and albuminuria, and medications prescribed. CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.72 m2 and/or albuminuria. RESULTS: The study population comprised of 5112 T2D patients with a mean (SD) age of 66.7 (13.0) years. Of these, 60.2% were screened for CKD with both eGFR and albuminuria, and 30.1% of these patients had CKD. The prevalence of moderately increased and severely increased albuminuria was 19.6% and 3.2%, respectively. A total of 57.0% of the study population received angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). CONCLUSIONS: Screening for CKD with both recommended measures (eGFR and albuminuria) was insufficiently performed among this T2D population. Additionally, just over half of the study population had been prescribed ACE inhibitors or ARB. These results suggest an incongruity between the gold standard of diabetes care and real-world clinical practice.
AIMS: To estimate the prevalence of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) in Finnish primary healthcare, and to evaluate the screening for CKD and the proportions of patients receiving antihyperglycemic and cardiovascular preventive medication. MATERIAL AND METHODS: T2D patients treated at the Rovaniemi Health Center, Finland during the years 2015-2019. Data included patient characteristics, blood pressure, HbA1c, lipid levels, kidney function and albuminuria, and medications prescribed. CKD was defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.72 m2 and/or albuminuria. RESULTS: The study population comprised of 5112 T2D patients with a mean (SD) age of 66.7 (13.0) years. Of these, 60.2% were screened for CKD with both eGFR and albuminuria, and 30.1% of these patients had CKD. The prevalence of moderately increased and severely increased albuminuria was 19.6% and 3.2%, respectively. A total of 57.0% of the study population received angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). CONCLUSIONS: Screening for CKD with both recommended measures (eGFR and albuminuria) was insufficiently performed among this T2D population. Additionally, just over half of the study population had been prescribed ACE inhibitors or ARB. These results suggest an incongruity between the gold standard of diabetes care and real-world clinical practice.
Authors: Peter Bramlage; Stefanie Lanzinger; Sascha R Tittel; Eva Hess; Simon Fahrner; Christoph H J Heyer; Mathias Friebe; Ivo Buschmann; Thomas Danne; Jochen Seufert; Reinhard W Holl Journal: BMC Nephrol Date: 2021-05-19 Impact factor: 2.388